OBJECTIVES: The objective of this study was to evaluate whether disparities in pancreatic cancer diagnosis, treatment, and survival are reduced in an integrated health system. METHODS: We conducted a retrospective study (2006-2014) among patients with pancreatic cancer from Kaiser Permanente Southern California. Racial ethnic groups included non-Hispanic whites (NHW), non-Hispanic blacks (NHB), Hispanics, and Asians. We used multivariable and Cox regression analyses to evaluate disparities in diagnosis and treatment utilization (oncology care, surgery, time to surgery, chemotherapy) and overall survival, respectively. RESULTS: Among 2103 patients, 54% were diagnosed with stage IV disease, 80% received oncology consultation, 20% received surgery with mean time to surgery 27 days (standard deviation, 36.8), 50.4% received chemotherapy. Mean overall survival was 8.6 months (standard deviation, 11.5). There were no differences in odds of stage IV diagnosis, oncology consultation, surgery, or time to surgery by racial ethnic group. Asians were more likely to receive chemotherapy (odds ratio, 1.59; 95% confidence interval [CI], 1.09-2.32) compared to NHW. NHB (hazard ratio, 0.78; 95% CI, 0.67-0.91) and Asians (hazard ratio, 0.81; 95% CI, 0.66-1.00) had improved survival compared to NHW. CONCLUSIONS: Minorities were not disadvantaged in pancreatic cancer care. Improved health care coordination may improve current disparities.
OBJECTIVES: The objective of this study was to evaluate whether disparities in pancreatic cancer diagnosis, treatment, and survival are reduced in an integrated health system. METHODS: We conducted a retrospective study (2006-2014) among patients with pancreatic cancer from Kaiser Permanente Southern California. Racial ethnic groups included non-Hispanic whites (NHW), non-Hispanic blacks (NHB), Hispanics, and Asians. We used multivariable and Cox regression analyses to evaluate disparities in diagnosis and treatment utilization (oncology care, surgery, time to surgery, chemotherapy) and overall survival, respectively. RESULTS: Among 2103 patients, 54% were diagnosed with stage IV disease, 80% received oncology consultation, 20% received surgery with mean time to surgery 27 days (standard deviation, 36.8), 50.4% received chemotherapy. Mean overall survival was 8.6 months (standard deviation, 11.5). There were no differences in odds of stage IV diagnosis, oncology consultation, surgery, or time to surgery by racial ethnic group. Asians were more likely to receive chemotherapy (odds ratio, 1.59; 95% confidence interval [CI], 1.09-2.32) compared to NHW. NHB (hazard ratio, 0.78; 95% CI, 0.67-0.91) and Asians (hazard ratio, 0.81; 95% CI, 0.66-1.00) had improved survival compared to NHW. CONCLUSIONS: Minorities were not disadvantaged in pancreatic cancer care. Improved health care coordination may improve current disparities.
Authors: Nadia N Khan; Tennille Lewin; Amy Hatton; Charles Pilgrim; Liane Ioannou; Luc Te Marvelde; John Zalcberg; Sue Evans Journal: Am J Cancer Res Date: 2022-02-15 Impact factor: 6.166
Authors: Andrea M Schiefelbein; John K Krebsbach; Amy K Taylor; Jienian Zhang; Chloe E Haimson; Amy Trentham-Dietz; Melissa C Skala; John M Eason; Sharon M Weber; Patrick R Varley; Syed N Zafar; Noelle K LoConte Journal: WMJ Date: 2022-07
Authors: Annabelle L Fonseca; Hamza Khan; Krista R Mehari; Deepa Cherla; Martin J Heslin; Fabian M Johnston Journal: Ann Surg Oncol Date: 2022-01-23 Impact factor: 5.344
Authors: Jennifer B Permuth; Ashley Clark Daly; Daniel Jeong; Jung W Choi; Miles E Cameron; Dung-Tsa Chen; Jamie K Teer; Tracey E Barnett; Jiannong Li; Benjamin D Powers; Nagalakshmi B Kumar; Thomas J George; Karla N Ali; Tri Huynh; Shraddha Vyas; Clement K Gwede; Vani N Simmons; Pamela J Hodul; Estrella M Carballido; Andrew R Judge; Jason B Fleming; Nipun Merchant; Jose G Trevino Journal: Cancer Med Date: 2019-05-09 Impact factor: 4.452
Authors: Scarlett Hao; Anastasios Mitsakos; William Irish; Janet Elizabeth Tuttle-Newhall; Alexander A Parikh; Rebecca A Snyder Journal: J Surg Oncol Date: 2022-03-22 Impact factor: 2.885
Authors: Valentina A Zavala; Paige M Bracci; John M Carethers; Luis Carvajal-Carmona; Nicole B Coggins; Marcia R Cruz-Correa; Melissa Davis; Adam J de Smith; Julie Dutil; Jane C Figueiredo; Rena Fox; Kristi D Graves; Scarlett Lin Gomez; Andrea Llera; Susan L Neuhausen; Lisa Newman; Tung Nguyen; Julie R Palmer; Nynikka R Palmer; Eliseo J Pérez-Stable; Sorbarikor Piawah; Erik J Rodriquez; María Carolina Sanabria-Salas; Stephanie L Schmit; Silvia J Serrano-Gomez; Mariana C Stern; Jeffrey Weitzel; Jun J Yang; Jovanny Zabaleta; Elad Ziv; Laura Fejerman Journal: Br J Cancer Date: 2020-09-09 Impact factor: 9.075